Scilex Holding Company Enters into Master Distributor Agreement with CH Trading Group LLC and AD Ports Group for the Distribution of ZTlido® in the Middle East and North Africa Region
April 17, 2023 09:00 ET
|
Scilex Holding Company
Designated Territories will include the United Arab Emirates, Qatar, Bahrain, Kuwait, Oman, and Egypt.CH Trading Group LLC will continue the process to expand commercialization of ZTlido® in the...
Scilex Holding Company Announces Final Postponement of Annual Meeting of Stockholders
April 14, 2023 18:32 ET
|
Scilex Holding Company
PALO ALTO, Calif., April 14, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced...
Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders
April 05, 2023 17:27 ET
|
Scilex Holding Company
PALO ALTO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today...
Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
March 27, 2023 09:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today...
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
March 21, 2023 09:00 ET
|
Scilex Holding Company
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products (ZTlido®, Gloperba® and Elyxyb™) for...
Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment
March 08, 2023 10:13 ET
|
Scilex Holding Company
CH Trading Group will serve as exclusive territories distributor in the Middle East and North Africa countries with US $105 million minimum purchase commitment.CH Trading Group to immediately start...
Scilex Holding Company announces the commercial launch of ELYXYBTM (celecoxib oral solution) in the U.S., strengthening its leadership position in non-opioid pain management
February 27, 2023 09:00 ET
|
Scilex Holding Company
ELYXYBTM is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 The U.S. oral migraine drug market size...
Scilex Announces New Medicaid Agreements with CA & FL
October 01, 2019 07:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is excited to announce that its...
Scilex Holding Company Strengthens Board of Directors with Appointment of Two Highly Accomplished Pharmaceutical and Biotechnology Executives, Scott Whitcup, M.D. and Elizabeth Czerepak
September 30, 2019 07:00 ET
|
Scilex Holding Company
PALO ALTO, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex) today announced that it appointed Scott M. Whitcup, M.D. as lead independent director to its Board of Directors...